Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE 39 Monodrugs, 2 Combination Drugs Designated: Quality Reevaluation
February 12, 2001
-
ARCHIVE Mochida to Prevail through R&D, Alliance, Emphasis on Results
February 12, 2001
-
ARCHIVE Keisansho to Promote Healthcare Services as Industry
February 12, 2001
-
ARCHIVE REGULATORY NEWS IN BRIEF -2-
February 12, 2001
-
ARCHIVE Dainippon to Withdraw Aleviatin Fine Granules
February 12, 2001
-
ARCHIVE Drug Makers Must Assume Full Responsibility for Their Products
February 12, 2001
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 12, 2001
-
ARCHIVE Bayer Yakuhin, Meiji Seika to Comarket Ciproxan
February 12, 2001
-
ARCHIVE Japan Not to Introduce Inactivated Vaccine against Polio
February 12, 2001
-
ARCHIVE Combination Therapy with Protopic, Steroid Reported: Fujisawa Seminar
February 12, 2001
-
ARCHIVE Kyorin Establishes Subsidiary to Gain Foothold in US Market
February 12, 2001
-
ARCHIVE Serious ADR Reported for Sarpogrelate
February 12, 2001
-
ARCHIVE Daiichi Starts Drug Discovery Research in New Laboratory
February 12, 2001
-
ARCHIVE Kirin Brewery Wins Epoetin Patent Suit Against Snow Brand Milk
February 12, 2001
-
ARCHIVE Typographical Error Found in NHI Price of Lorcam Presented to Chuikyo
February 12, 2001
-
ARCHIVE More Than 80% of Clinics Selected Fixed Sum Copayment: PJ Survey
February 5, 2001
-
ARCHIVE Boston Scientific Japan: New Balloon Catheters for PTCA
February 5, 2001
-
ARCHIVE 80.7% of Clinics Select Fixed Sum Copayment
February 5, 2001
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
February 5, 2001
-
ARCHIVE Takeda to Carry Out Reform with Global Standard: President Takeda
February 5, 2001
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…